Seelos Therapeutics Announces Dosing of the First Patients in a Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder Jan 15 • 4 min read Seelos Therapeutics, Inc. announced dosing of the first patients in its registrational Proof of Concept study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder.
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience Jan 14 • 3 min read MindMed announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer.
Novamind Expands Psychedelic Medicine Access in Utah Jan 13 • 2 min read Novamind Inc. announced the expansion and optimization of its Cedar Psychiatry clinic in Layton, Utah.
PharmaTher Approved to Trade on the OTCQB Venture Market Jan 13 • 2 min read Newscope Capital Corporation, who through its wholly-owned subsidiary, PharmaTher Inc., announced that its common shares have been approved for trading on the OTCQB® Venture Market effective today.
MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers Jan 12 • 3 min read MindMed announced an innovative randomized placebo-controlled study evaluating the effects of daytime and evening administration of low doses of LSD on cognitive performance.